Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation

被引：19

作者：

Howard, Jason D. ^{[1
]}

Lu, Bo ^{[2
]}

Chung, Christine H. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA

[2] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA

来源：

ORAL ONCOLOGY | 2012年 / 48卷 / 01期

关键词：

HNSCC; Targeted therapies; EGFR; PIK3CA; TP53; P16; TGF-beta; NF-kappa B; Notch1; HPV; GENE COPY NUMBER; FACTOR-KAPPA-B; BETA SIGNALING PATHWAY; IN-SITU HYBRIDIZATION; HUMAN-PAPILLOMAVIRUS; PLUS CETUXIMAB; TUMOR-SUPPRESSOR; MUTANT P53; C-MET; CANCER;

D O I：

10.1016/j.oraloncology.2011.09.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Head and neck squamous cell carcinoma (HNSCC) encompasses a diverse group of malignancies originating in the oral cavity, oropharynx, larynx and hypopharynx. Although treatment modalities have improved, carefully designed biomarker-driven clinical trials will yield the best opportunities to enhance HNSCC therapy options in the future. Due to the heterogeneous nature of HNSCC, discovering a "silver bullet" for the treatment of HNSCC is unlikely. Consequently, impactful HNSCC clinical trials will require multiple assay platforms and expanded technical expertise. In this review, we will outline pathways critical to HNSCC oncogenesis and highlight signaling nodes within these pathways that represent biomarkers for prognosis and potential targeted therapies. All treatment modalities are subject to mechanisms of resistance; thus, lessons learned from HNSCC investigations and studies of similar targeted agents in other pertinent malignancies will be discussed. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：10 / 17

页数：8

共 92 条

[11] Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model [J].

Belinsky, Steven A. ;

Grimes, Marcie J. ;

Picchi, Maria A. ;

Mitchell, Hugh D. ;

Stidley, Chris A. ;

Tesfaigzi, Yohannes ;

Channell, Meghan M. ;

Liu, Yanbin ;

Casero, Robert A., Jr. ;

Baylin, Stephen B. ;

Reed, Mathew D. ;

Tellez, Carmen S. ;

March, Thomas H. .

CANCER RESEARCH, 2011, 71 (02) :454-462

[12] Progressive Tumor Formation in Mice with Conditional Deletion of TGF-β Signaling in Head and Neck Epithelia Is Associated with Activation of the PI3K/Akt Pathway [J].

Bian, Yansong ;

Terse, Anita ;

Du, Juan ;

Hall, Bradford ;

Molinolo, Alfredo ;

Zhang, Pin ;

Chen, Wanjun ;

Flanders, Kathleen C. ;

Gutkind, J. Silvio ;

Wakefield, Lalage M. ;

Kulkarni, Ashok B. .

CANCER RESEARCH, 2009, 69 (14) :5918-5926

[13] High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma [J].

Bindhu, O. S. ;

Ramadas, K. ;

Sebastian, Paul ;

Pillai, M. Radhakrishna .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2006, 28 (10) :916-925

[14] Notch signaling in development and cancer [J].

Bolos, Victoria ;

Grego-Bessa, Joaquin ;

de la Pompa, Jose Luis .

ENDOCRINE REVIEWS, 2007, 28 (03) :339-363

[15] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[16] Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma [J].

Brieger, Juergen ;

Pongsapich, Warut ;

Mann, Sylvia A. ;

Hedrich, Jana ;

Fruth, Kai ;

Pogozelski, Benjamin ;

Mann, Wolf J. .

ORAL ONCOLOGY, 2010, 46 (09) :678-683

[17] Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study [J].

Burtness, B ;

Goldwasser, MA ;

Flood, W ;

Mattar, B ;

Forastiere, AA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8646-8654

[18] Regulation of p53 Family Member Isoform ΔNp63α by the Nuclear Factor-κB Targeting Kinase IκB Kinase β [J].

Chatterjee, Aditi ;

Chang, Xiaofei ;

Sen, Tanusree ;

Ravi, Rajani ;

Bedi, Atul ;

Sidransky, David .

CANCER RESEARCH, 2010, 70 (04) :1419-1429

[19] The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck [J].

Chau, Nicole G. ;

Perez-Ordonez, Bayardo ;

Zhang, Katherine ;

Nhu-An Pham ;

Ho, James ;

Zhang, Tong ;

Ludkovski, Olga ;

Wang, Lisa ;

Chen, Eric X. ;

Tsao, Ming-Sound ;

Kamel-Reid, Suzanne ;

Siu, Lillian L. .

HEAD & NECK ONCOLOGY, 2011, 3

[20] Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma [J].

Chung, Christine H. ;

Parker, Joe S. ;

Ely, Kim ;

Carter, Jesse ;

Yi, Yajun ;

Murphy, Barbara A. ;

Ang, K. Man ;

El-Naggar, Adel K. ;

Zanation, Adam M. ;

Cmelak, Anthony J. ;

Levy, Shawn ;

Slebos, Robbert J. ;

Yarbrough, Wendell G. .

CANCER RESEARCH, 2006, 66 (16) :8210-8218

← 1 2 3 4 5 6 7 8 9 10 →